{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"53.8","value":"95.98"},{"groupId":"OG001","spread":"51.4","value":"91.27"},{"groupId":"OG002","spread":"69.9","value":"123.75"},{"groupId":"OG003","spread":"56.5","value":"65.36"},{"groupId":"OG004","spread":"31.4","value":"59.07"},{"groupId":"OG005","spread":"51.0","value":"69.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"title":"CL Hx-DR5-01 Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"70.2","value":"77.36"},{"groupId":"OG001","spread":"51.8","value":"79.97"},{"groupId":"OG002","spread":"72.6","value":"155.76"},{"groupId":"OG003","spread":"31.8","value":"58.07"},{"groupId":"OG004","spread":"28.0","value":"73.43"},{"groupId":"OG005","spread":"2.0","value":"36.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"title":"CL Hx-DR5-01 Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"57.1","value":"99.53"},{"groupId":"OG001","spread":"76.0","value":"131.46"},{"groupId":"OG002","spread":"12.9","value":"111.33"},{"groupId":"OG003","spread":"42.5","value":"62.90"},{"groupId":"OG004","spread":"26.1","value":"62.64"},{"comment":"Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.","groupId":"OG005","spread":"NA","value":"37.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"}],"units":"Participants"}],"title":"CL Hx-DR5-01 Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"62.5","value":"111.10"},{"groupId":"OG001","spread":"51.3","value":"116.89"},{"groupId":"OG002","spread":"69.3","value":"127.35"},{"groupId":"OG003","spread":"37.4","value":"67.28"},{"groupId":"OG004","spread":"29.2","value":"69.39"},{"groupId":"OG005","spread":"53.9","value":"81.96"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"title":"CL Hx-DR5-05 Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"69.4","value":"90.18"},{"groupId":"OG001","spread":"67.1","value":"90.45"},{"groupId":"OG002","spread":"240.7","value":"131.51"},{"groupId":"OG003","spread":"28.8","value":"79.72"},{"groupId":"OG004","spread":"51.9","value":"134.11"},{"groupId":"OG005","spread":"3.7","value":"40.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"title":"CL Hx-DR5-05 Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"50.5","value":"143.09"},{"groupId":"OG001","spread":"77.3","value":"140.38"},{"groupId":"OG002","spread":"42.2","value":"68.57"},{"groupId":"OG003","spread":"59.8","value":"114.74"},{"groupId":"OG004","spread":"78.9","value":"172.66"},{"comment":"Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.","groupId":"OG005","spread":"NA","value":"41.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"}],"units":"Participants"}],"title":"CL Hx-DR5-05 Cycle 3 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"description":"The CL of Hx-DR5-01 and Hx-DR5-05 are reported.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received 0.1 mg/kg of GEN1029 every 2 weeks (Q2W) until the end of treatment.","id":"OG000","title":"Biweekly Regimen (GEN1029 0.1 mg/kg)"},{"description":"Participants received 0.2 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG001","title":"Biweekly Regimen (GEN1029 0.2 mg/kg)"},{"description":"Participants received 0.3 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG002","title":"Biweekly Regimen (GEN1029 0.3 mg/kg)"},{"description":"Participants received 1.0 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG003","title":"Biweekly Regimen (GEN1029 1.0 mg/kg)"},{"description":"Participants received 2.0 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG004","title":"Biweekly Regimen (GEN1029 2.0 mg/kg)"},{"description":"Participants received 3.0 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG005","title":"Biweekly Regimen (GEN1029 3.0 mg/kg)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set included all participants who were exposed to at least 1 dose of GEN1029 and who had at least 1 post-dose PK measurement. 'Number analyzed' denotes the number of participants evaluated for the specified time point.","reportingStatus":"POSTED","timeFrame":"Predose, end of infusion, 2, 4, 24, 48, 168 and 336 hours after end of infusion on Day 1 of Cycles 1, 2, 3","title":"Total Clearance (CL) of Hx-DR5-01 and Hx-DR5-05","type":"SECONDARY","unitOfMeasure":"mL/h"}